Abstract:Abstract Introduction: Gastric carcinoma (GC) is a leading cause of cancer mortality worldwide, and is highly prevalent in China. Loss of imprinting (LOI) of insulin-like growth factor II (IGF-2) gene is an important epigenetic phenomenon related to carcinogenesis and tumor progression in many human cancers. To date, however, few studies have evaluated the IGF-2 LOI in GC. Aims: This study aimed: (1) to examine the prevalence of LOI of IGF-2 in tumor, matched normal gastric mucosa, and peripheral blood lymphocyte (PBL) from a well characterized series of patients with GC, and in PBL from a control group, (2) To examine the association of LOI of IGF-2 with circulating IGF-2 and tissue IGF-2 expression. Methods: IGF-2 genomic imprinting status was analyzed by PCR and RT-PCR followed by restrictive endonuclease (Apa I) digestion. Prevalence of LOI in PBL from 33 Apa I informative GC patients (21 males, age: 59.91±13.87) was compared with that from 21 informative controls (13 males, age: 56.81±13.28). Findings were also associated with the clinicopathologic parameters in patients with GC. IGF-2 level in peripheral blood (ng/ml) and tumor were determined with ELISA and immunohistochemical staining, respectively. Results: LOI of IGF-2 was positive in 48.48% (16/33) GC tumor, 21.21% (7/33) adjacent mucosa (AM), 12.12% (4/33) distant mucosa (DM), and 15.15% (5/33) PBL. The prevalence of LOI in PBL was not significantly different between GC patients (5/33, 15.15%) and controls (2/21, 9.52%) (p=0.693). Patients with LOI-positive tumor were more likely to be advanced stage (93.75% vs. 58.82%, p=0.039) or have positive lymph nodes (87.50% vs. 52.94%, p=0.057). Significantly increased blood IGF-2 level was seen in GC patients with LOI-positive tumor (808.07±255.25) when compared with those with LOI-negative tumor (396.21±198.94) (p<0.01). The positive rate of IGF-2 staining was significantly higher in tumor (10 of 16, 62.50%), AM (7 of 7, 100.00%), and DM (3 of 4, 75.00%) with LOI than that in tissues without LOI (tumor: 2 of 17, 11.76%; AM: 2 of 26, 7.69%; DM: 2 of 29, 6.90%) (p<0.01). Conclusions: The results of this study suggest that IGF-2 is a critical factor in carcinogenesis and progression of GC, with LOI of IGF-2 modulating tissue and circulating expression of IGF-2. IGF-2 LOI may represent a potential epigenetic marker for gastric cancer risk, prognosis and treatment stratification. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 194.

Loss of Insulin-Like Growth Factor II Imprinting is a Hallmark Associated with Enhanced Chemo/radiotherapy Resistance in Cancer Stem Cells

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

IGF2 loss of imprinting enhances colorectal cancer stem cells pluripotency by promoting tumor autophagy

Restoration of IGF2 Imprinting by Polycomb Repressive Complex 2 Docking Factor SUZ12 in Colon Cancer Cells

Promoter Histone H3K27 Methylation in the Control of IGF2 Imprinting in Human Tumor Cell Lines.

The role of IGF/IGF-1R signaling in the regulation of cancer stem cells

Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients.

Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma is Associated with Increased Autocrine of IGF1.

IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness

Targeted tumor gene therapy based on loss of IGF2 imprinting.

Interruption of Intrachromosomal Looping by CCCTC Binding Factor Decoy Proteins Abrogates Genomic Imprinting of Human Insulin-Like Growth Factor II.

[Genomic Imprinting of Insulin-Like Growth Factor II in Prostate Cancer and Its Clinical Significance].

Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells

Enhanced Sensitivity to IGF-II Signaling Links Loss of Imprinting Ofigf2to Increased Cell Proliferation and Tumor Risk

Abstract 194: Loss of Imprinting and Abnormal Expression of Insulin-Like Growth Factor II in Gastric Cancer

p52-ZER6/IGF1R axis maintains cancer stem cell population to promote cancer progression by enhancing pro-survival mitophagy

Pluripotency transcription factors and cancer stem cells: small genes make a big difference

Loss of Imprinting and Abnormal Expression of the Insulin-Like Growth Factor 2 Gene in Gastric Cancer

Role of hypoxia inducible factor-1 in cancer stem cells

Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy

The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells